191 related articles for article (PubMed ID: 32783372)
1. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
[TBL] [Abstract][Full Text] [Related]
2. Histologic lung cancer subtype differentiates synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases.
Cheng H; Lei BF; Peng PJ; Lin YJ; Wang XJ
J Surg Res; 2017 May; 211():215-222. PubMed ID: 28501120
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
4. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
5. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
6. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy.
Zhang C; Yin K; Liu SY; Yan LX; Su J; Wu YL; Zhang XC; Zhong WZ; Yang XN
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820821
[TBL] [Abstract][Full Text] [Related]
7. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Vergnenegre A; Geier M; Guisier F; Lamy R; Comet B; Le Garff G; Do P; Janicot H; Morel H; Decroisette C; Andre M; Falchero L; Paleiron N; Monnet I;
Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
Kumar S; Joga S; Biswas B; Dabkara D; Prasad KT; Singh N; Malik PS; Khurana S; Ganguly S; Muthu V; Batra U
Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
[TBL] [Abstract][Full Text] [Related]
9. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
Wu N; Yang X; Zhai Y; Lu W
J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
11. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
12. A surgical Case of Synchronous Multiple Primary Lung Cancers with Small Cell Carcinoma and Squamous Cell Carcinoma.
Watanabe H; Tomita S; Ikoma Y; Kohno M; Masuda R; Iwazaki M
Tokai J Exp Clin Med; 2021 Apr; 46(1):29-32. PubMed ID: 33835473
[TBL] [Abstract][Full Text] [Related]
13. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
15. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
17. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
18. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
19. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.
Karayama M; Yoshizawa N; Sugiyama M; Mori K; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Goshima S; Suda T; Takehara Y
Lung Cancer; 2020 May; 143():47-54. PubMed ID: 32203770
[TBL] [Abstract][Full Text] [Related]
20. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review.
Xie W; Hu N; Cao L
Front Immunol; 2021; 12():790051. PubMed ID: 34956221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
